Nurix Showcases 92.9% Response Rate for Bexobrutideg in Tough-to-Treat CLL—Updated Phase 1 Results Reveal Consistent Safety and Durability
Market Chameleon (Thu, 11-Jun 11:08 AM)
Roche and Nurix Ink $2.3 Billion Deal: Novel BTK Degrader Targets Resistant Blood Cancers, Immunology, and Neurology
Market Chameleon (Mon, 8-Jun 9:55 AM)
